MedPath

Zyvox

These highlights do not include all the information needed to use ZYVOX safely and effectively. See full prescribing information for ZYVOX. ZYVOX (linezolid) injection, tablets and oral suspension Initial U.S. Approval: 2000

Approved
Approval ID

ce57225b-4580-442b-8c48-8045297cbb50

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Sep 3, 2018

Manufacturers
FDA

Fresenius Kabi Norge As

DUNS: 731170932

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

LINEZOLID

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code66298-5137
Application NumberNDA021131
Product Classification
M
Marketing Category
C73594
G
Generic Name
LINEZOLID
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateSeptember 3, 2018
FDA Product Classification

INGREDIENTS (4)

DEXTROSE, UNSPECIFIED FORMInactive
Code: IY9XDZ35W2
Classification: IACT
LINEZOLIDActive
Quantity: 200 mg in 100 mL
Code: ISQ9I6J12J
Classification: ACTIB
SODIUM CITRATE, UNSPECIFIED FORMInactive
Code: 1Q73Q2JULR
Classification: IACT
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QP
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Zyvox - FDA Drug Approval Details